Introduction {#cesec10}
============

Schizophrenia is associated with significant personal, social, and economic costs. The mortality risk associated with schizophrenia is also a major concern---eg, a recent systematic review and meta-analysis found that people with a diagnosis of schizophrenia die an average of 14·5 years earlier than those without diagnosed schizophrenia.[@bib1] About a third of people with a diagnosis of schizophrenia respond poorly to standard treatment with antipsychotic medication. Treatment-resistant schizophrenia is defined as schizophrenia treated over two periods with different antipsychotics at an adequate dose for at least 4 weeks, and symptoms are not reduced by at least 20%.[@bib2] 8 million people are estimated to have treatment-resistant schizophrenia.[@bib3] For people meeting diagnostic criteria for treatment-resistant schizophrenia, economic costs are greater because of longer-term residential and intensive community treatment,[@bib4] quality of life is 20% lower,[@bib5] and community functioning is poorer than those individuals with a diagnosis of schizophrenia that is not resistant to treatment with antipsychotic medication.[@bib6]

Research in context**Evidence before this study**For people with a diagnosis of schizophrenia who respond poorly to standard treatment with antipsychotic medication, the antipsychotic clozapine is generally considered to be the treatment of choice. However, 30--40% of people who trial clozapine can have a poor response to the medication and the range of adverse effects can prevent the optimal dose being reached or tolerated long term. We searched PubMed from inception to Feb 28, 2018, for publications in English, using the terms "clozapine resistant schizophrenia" and "treatment". Our search yielded 24 publications, of which four were small randomised controlled trials (RCTs) of pharmacological or biological treatments for people with clozapine-resistant schizophrenia and four were systematic reviews and meta-analyses of pharmacological or biological augmentation strategies. No RCTs of psychological treatments for clozapine-resistant schizophrenia were found. Evidence for pharmacological and psychological treatments for people who meet criteria for clozapine-resistant schizophrenia is limited by small studies providing low-quality evidence.**Added value of this study**The reduction in psychiatric symptoms observed at the end of treatment with cognitive behavioural therapy is of a similar magnitude to that reported for pharmacological augmentation. However, there appear to be fewer side-effects associated with cognitive behavioural therapy, and the evidence for symptom reduction at end of treatment is of higher quality than that for pharmacological augmentation.**Implications of all the available evidence**There is insufficient evidence to support offering cognitive behavioural therapy to all patients with clozapine-resistant schizophrenia. A pragmatic individual trial might be indicated for some individuals, particularly when the person prefers talking therapy to pharmacological augmentation as their treatment choice.

Clozapine is generally considered the treatment of choice for people with treatment-resistant schizophrenia,[@bib7] which is reflected in recommendations in clinical guidelines. However, 30--40% of patients show an inadequate response to clozapine.[@bib8] Debate exists about the superiority of clozapine for treatment-resistant schizophrenia, with one network meta-analysis finding clozapine to be equivalent to many other antipsychotics for treatment-resistant schizophrenia.[@bib9] However, another meta-analysis found clozapine to be superior to all other antipsychotics for positive symptoms.[@bib10]

Some people cannot tolerate clozapine; serious side-effects include seizures and agranulocytosis. Poor response to clozapine, termed clozapine-resistant schizophrenia, is defined as inadequate response to treatment for at least 12 weeks at a stable dose of 400 mg or more per day, unless limited by side-effects. The most common treatment of clozapine-resistant schizophrenia is augmentation with another antipsychotic medication.[@bib11] Although meta-analyses have found some evidence of small benefits of such augmentation,[@bib12], [@bib13], [@bib14] this evidence is limited by few, small, low-quality studies. A small study examined the effects of augmentation with electro-convulsive therapy in 39 participants, but this was of short duration (8 weeks).[@bib15]

Several meta-analyses of cognitive behavioural therapy (CBT) have found small to moderate effects on psychotic symptoms when delivered in combination with anti-psychotic medications.[@bib16], [@bib17], [@bib18] However, conclusions regarding the efficacy of CBT are claimed to be mistaken, since most large, well conducted trials have not shown a significant effect at the end of treatment and the effect sizes are reduced overall if meta-analyses are limited to studies of high quality.[@bib17] The efficacy of augmentation of clozapine with CBT for clozapine-resistant schizophrenia is unknown, since only one small unrandomised trial has investigated this. [@bib19]

The Focusing On Clozapine Unresponsive Symptoms (FOCUS) trial aimed to determine whether CBT is clinically effective for people with clozapine-resistant schizophrenia. We hypothesised that CBT plus treatment as usual would reduce the psychiatric symptoms of schizophrenia, improve quality of life, and improve user-defined recovery over a 21-month follow-up period compared with treatment as usual alone.

Methods {#cesec20}
=======

Study design and participants {#cesec30}
-----------------------------

FOCUS was a pragmatic, parallel group, prospective, randomised, open trial with masked evaluation of outcomes, comparing CBT plus treatment as usual with treatment as usual alone in individuals unable to tolerate clozapine, or whose symptoms did not respond to the drug. We recruited participants through referrals from community-based and inpatient mental health services in five sites in the UK. The National Research Ethics Committee approved the FOCUS trial. Full details of the protocol are provided elsewhere.[@bib20]

The inclusion criteria were: (1) persistent symptoms despite an adequate trial of clozapine in terms of dose, duration, and adherence,[@bib11] defined as treatment with clozapine at a stable dose of 400 mg or more (unless limited by tolerability) for at least 12 weeks, or if currently augmented with a second antipsychotic that had been given for at least 12 weeks, without remission of psychotic symptoms, or discontinuation of clozapine because of adverse reactions or inefficacy in the past 24 months; (2) presence of at least one psychotic symptom with a severity of 4 or more (for hallucinations or delusions) or 5 or more (for suspiciousness or grandiosity) on the Positive and Negative Syndrome Scale (PANSS), plus a PANSS total score of at least 58, which is equivalent to a clinical global impression of being at least mildly ill;[@bib21] (3) in contact with mental health services and have a care coordinator; (4) meet either ICD-10 criteria for schizophrenia, schizoaffective disorder, or delusional disorder, or criteria for an Early Intervention for Psychosis service to allow for diagnostic uncertainty in early phases; (5) aged 16 years or older; and (6) competent and willing to provide written, informed consent.

Our exclusion criteria were primary diagnosis of alcohol or substance dependence, developmental disability, non-English speaking, and having received CBT within the past 12 months.

Potential participants were given an information sheet and, if willing to participate and provide written informed consent, they were offered an assessment.

Randomisation and masking {#cesec40}
-------------------------

Randomisation was 1:1 by use of randomised-permuted blocks of random size (block sizes of four or six), stratified by centre and administered via a study-specific web-based portal. Allocation was notified to the trial manager, trial administrator, and trial therapists by email and to the participant by letter. Research assistants assessing outcomes were masked to allocation to protect against rater bias and allegiance bias. Masking was maintained with a wide range of measures, described in detail in our protocol.[@bib20] If a blind break occurred, where possible, a new research assistant masked to allocation was identified for subsequent follow-up assessments.

Procedures {#cesec50}
----------

CBT was delivered by appropriately qualified psychological therapists on an individual basis over a period of 9 months and included up to 26 h of treatment on an approximately weekly basis over the 9-month treatment window with up to four additional booster sessions in the following year. CBT was based on a specific cognitive model[@bib22] and used a manualised approach based on an individualised formulation:[@bib23] the chief investigator developed the model and manualised approach. CBT is a collaborative therapy that is problem orientated, working towards shared goals. Thus, treatment targets often included positive symptoms, but also included social issues (eg, improvement of relationships or development of meaningful roles) and emotional difficulties (eg, anxiety and depression). Fidelity to the treatment protocol was ensured by a combination of an initial week of training on the use of the specific model and manual, weekly supervision sessions, and quarterly training days, and was assessed by rating audio recordings of therapy sessions by use of the Cognitive Therapy Scale--Revised.[@bib24] Further details regarding establishing and monitoring adherence are provided elsewhere.[@bib20]

The comparator was treatment as usual, which included care coordination from secondary care mental health services, including community mental health teams, early intervention in psychosis, or inpatient settings. All patients received follow-up from a multidisciplinary team within secondary mental health services. We did not ask services to withhold any treatment. All treatments in both conditions were monitored by use of an Economic Patient Questionnaire.

Outcomes {#cesec60}
--------

The primary outcome was total PANSS score at 21 months. The PANSS is a 30 item rating scale designed to provide a comprehensive assessment of psychiatric symptoms in adult patients with schizophrenia. Five components have been reported: positive, negative, depression-anxiety, agitation-excitement, and disorganisation.[@bib25] The PANSS was completed at baseline assessment, end of treatment (9 months), and 1-year follow-up (21 months). PANSS total score at 21 months was selected as the primary outcome because the durability of any treatment effect observed at the end of treatment was considered the most important criterion.

We collected secondary outcome measures at the timepoints mentioned earlier: the Psychotic Symptom Rating Scales (PSYRATS)[@bib26] to assess dimensions of auditory hallucinations and delusional beliefs; the Personal and Social Performance Scale to assess social functioning;[@bib27] the Calgary Depression Rating Scale for Schizophrenia to assess depression;[@bib28] and the Clinical Global Impression Scale (CGI)[@bib29] and a participant version (CGI-P) to obtain clinician and participant perception of global illness severity. Self-report questionnaires were used to assess self-rated recovery (the brief, 15 item Questionnaire about the Process of Recovery),[@bib30] health status and health-related utility (EQ-5D-5L),[@bib31] anxiety (meta-worry subscale of the Anxious Thoughts Inventory),[@bib32] alcohol use (Alcohol Use Disorder Test),[@bib33] and drug use (Drug Abuse Screening Test).[@bib34] An economic evaluation was also done, which will be reported elsewhere. The measure of health benefit was the quality-adjusted life-years derived from the health status and health-related utility questionnaire.

We recorded all events that met UK National Research Ethics Committee criteria for a serious adverse event---ie, serious negative events that are unexpected and deemed to be associated with the trial protocol or procedures. Additional unwanted effects of trial participation were defined as more than a 25% increase on PANSS total score or scoring 6+ on the CGI-Improvement Scale. We also developed a bespoke measure of potential unwanted effects of trial participation.

Statistical analysis {#cesec70}
--------------------

We calculated our sample to detect a difference in means between groups using a standardised effect size of 0·33 for 90% power and two-sided α of 5%. We required outcome data on 194 participants per group, using our modelling approach to increase precision rather than potentially reduce sample size. To account for 20% missing data, we inflated the sample size to 485. Statistical analysis was done after all participants completed 21 months of follow-up. This analysis followed a prespecified plan. Continuous variables were summarised using mean (SD) or median (IQR), and discrete variables were reported as absolute number and percentage. The primary outcome was analysed with repeated measures from linear mixed models that adjusted for prespecified baseline covariates (baseline PANSS, sex, and age) and included a random effect for site. Treatment effects are presented with 95% CIs for each timepoint. Additionally, the results of the primary analysis are expressed in the standardised mean difference scale to assist in the interpretation of our results compared with our hypothesised effect. The primary analysis was by randomised treatment based on intention to treat for all patients for whom data were available. To estimate treatment efficacy, we estimated complier average casual effects using instrumental variable methods. Secondary outcomes were analysed with linear mixed models, and adverse events were analysed with a χ^2^ test or logistic regression. We made no adjustments to secondary outcome CIs for multiple testing. Use of these linear mixed models allowed for the analysis of all available data, on the assumption that data were missing at random,[@bib35] conditional on covariates. Sensitivity analysis by use of multiple imputation on the primary outcome was done as well as the removal of participants who discontinued clozapine because of side-effects. We used estimated treatment effects adjusted for non-attendance at CBT with Complier Average Causal Effect models using two-stage least squares. We report the primary outcome showing improvement from baseline using 20%, 25%, 50%, and 75% thresholds, and the corresponding number needed to treat to aid interpretation. Additionally, we report the PANSS outcomes by severity based on inclusion criteria (delusions or hallucinatory behaviour with a score of 4 or greater and grandiosity or suspiciousness persecution with a score of 5 or greater). All analyses used Stata version 14·0. The Independent Data Monitoring Committee monitored accumulating unblinded data throughout the trial.

This study was prospectively registered, number ISRCTN99672552.

Role of the funding source {#cesec80}
--------------------------

The funder had no role in data collection, data analysis, data interpretation or writing of the report. The corresponding author had full access to all the data and had final responsibility to submit for publication.

Results {#cesec90}
=======

We identified 898 potentially eligible participants, of whom 565 (63%) met criteria for further assessment between Jan 1, 2013, and May 31, 2015. We randomly assigned 487 (86%) of 565 participants who met inclusion criteria and agreed to take part in either CBT plus treatment as usual (n=242) or treatment as usual alone (n=245; [figure](#fig1){ref-type="fig"}). Participants recruited via Early Intervention in Psychosis services (n=8) all met criteria for an ICD-10 schizophrenia spectrum diagnosis. Details of ineligibility are shown in the [appendix](#sec1){ref-type="sec"}. Analysis included 209 in the CBT group and 216 in the treatment as usual group. Baseline clinical and demographic data are shown in [table 1](#tbl1){ref-type="table"}; the groups were balanced across characteristics. Participants assigned to CBT plus treatment as usual received a median of 21 CBT sessions (IQR 12--25) within the 9-month treatment window; 213 (88%) of 242 attended six or more sessions, with only 12 (5%) participants attending no sessions ([appendix](#sec1){ref-type="sec"}). At 9 months, 51 blind breaks had occurred (23 of these patients were transferred to a new assessor, so 28 remained unblinded). By 21 months, there were 55 blind breaks (35 patients were transferred to a new assessor, so 20 remained unblinded). PANSS outcome at baseline by severity based on inclusion criteria showed no difference between the groups ([appendix](#sec1){ref-type="sec"}).FigureTrial profileCBT=cognitive behaviour therapy. PANSS=Positive and Negative Syndrome Scale.Table 1Baseline characteristics**Treatment as usual (n=245)Cognitive behavioural therapy plus treatment as usual (n=242)**Age, years42·8 (10·4)42·2 (10·7)SexMale173 (71%)176 (73%)Female72 (29%)66 (27%)EthnicityWhite222 (91%)222 (92%)Asian4 (2%)9 (4%)Black3 (1%)5 (2%)Mixed12 (5%)4 (2%)Other3 (1%)2 (1%)Refused to answer1 (\<1%)..EmploymentPaid, full or part time10 (4%)10 (4%)Voluntary16 (7%)14 (6%)Education or training5 (2%)9 (4%)Other unpaid activity8 (3%)6 (3%)Unemployed204 (83%)203 (84%)Missing2 (1%)..Residential statusInpatient16 (7%)17 (7%)Rehabilitation ward8 (3%)13 (5%)Supported accommodation45 (18%)39 (16%)Independent living174 (71%)172 (71%)Missing2 (1%)1 (\<1%)Full-time education, years12 (11--14); 22912 (11--14); 223Untreated psychosis, months18 (2--48); 2038 (1--24); 195Illness, months240 (144--300); 231216 (132--300); 227Diagnosis at baselineSchizophrenia218 (89%)209 (86%)Schizoaffective20 (8%)28 (12%)Delusional disorder5 (2%)2 (1%)Unspecified psychosis[\*](#tbl1fn1){ref-type="table-fn"}1 (\<1%)2 (1%)Missing1 (\<1%)1 (\<1%)Prescribed clozapine221 (90%)223 (92%)Time on clozapine, months60 (24--120); 21660 (24--120); 218Clozapine dose, mg400 (300--500); 221400 (300--525); 221Discontinued clozapine24 (10%)19 (8%)Time discontinued, months13 (3--20); 249 (5--13); 19Reasons for discontinuing clozapineSide-effects23 (96%)16 (84%)Lack of efficacy1 (4%)3 (16%)Taking other antipsychotic medicationNone142 (58%)136 (56%)One95 (39%)99 (41%)Two7 (3%)7 (3%)Three1 (\<1%)..Other medicationAntidepressants129 (53%)113 (47%)Other mental health medication35 (14%)52 (22%)Benzodiazepines30 (12%)27 (11%)Medication for antipsychotic side-effects24 (10%)27 (11%)[^2][^3]

Mean PANSS scores improved in both randomised groups over time from a mean of 83 at baseline ([table 2](#tbl2){ref-type="table"}). At 21 months, no difference occurred between the groups on PANSS total score (−0·89, 95% CI −3·32 to 1·55; p=0·48), although at 9 months, a small difference occurred between the groups in favour of CBT on PANSS total (−2·40, −4·79 to −0·02; p=0·049). This difference is equivalent to an effect size of −0·16 (95% CI −0·32 to −0·001) at 9 months and −0·06 (95% CI −0·21 to 0·10) at 21 months using the standardised mean difference scale. Multiple imputation sensitivity analysis gave similar results ([appendix](#sec1){ref-type="sec"}). Removal of participants who discontinued clozapine because of side-effects at baseline overall gave similar results ([appendix](#sec1){ref-type="sec"}). The adjustment for receiving at least six sessions of CBT had little effect on treatment effect estimates due to high compliance proportions: at 9 months, the Complier Average Causal Effect estimate was −2·50 (95% CI −5·10 to 0·11; p=0·060) and −0·87 (−3·69 to 1·96; p=0·55) at 21 months ([appendix](#sec1){ref-type="sec"}). We also estimated that the effect of each extra treatment session resulted in a change in PANSS total score of −0·12 (95% CI −0·24 to 0·00, p=0·059). Treatment effect estimates followed a similar pattern for other PANSS outcomes ([Table 2](#tbl2){ref-type="table"}, [Table 3](#tbl3){ref-type="table"}). At 21 months, 28 (13%) of 209 participants in the CBT plus treatment as usual group and 14 (7%) of 216 in the treatment as usual alone group had more than 50% improvement in PANSS (number needed to treat 15, 95% CI 8 \[number needed to treat, benefit\] to 81 \[number needed to treat, benefit\]).Table 2PANSS outcomes**Treatment as usual (n=245)Cognitive behavioural therapy plus treatment as usual (n=242)Mean difference (95% CI)p valuePANSS total**Baseline83·3 (14·0); 24582·8 (13·7); 242\....9 months77·8 (14·6); 22475·2 (15·5); 218−2·40 (−4·79 to −0·02)0·04921 months74·1 (14·8); 21673·0 (16·7); 209−0·89 (−3·32 to 1·55)0·48**PANSS positive**Baseline25·2 (5·7); 24524·7 (5·9); 242\....9 months23·6 (6·2; 22521·7 (6·6); 218−1·56 (−2·53 to −0·59)0·00221 months22·5 (6·1); 21621·3 (7·0); 209−0·85 (−1·84 to 0·15)0·095**PANSS negative**Baseline19·4 (6·4); 24519·3 (6·1); 242\....9 months18·6 (6·7); 22718·1 (7·0); 220−0·49 (−1·48 to 0·49)0·3321 months17·5 (6·1); 21617·8 (6·8); 2110·29 (−0·72 to 1·29)0·58**PANSS disorganised**Baseline24·8 (6·6); 24524·7 (6·5); 242\....9 months23·1 (6·0); 22523·2 (6·4); 218−0·01 (−0·91 to 0·88)0·9821 months22·4 (6·2); 21622·7 (6·6); 2100·14 (−0·78 to 1·05)0·77**PANSS excitement**Baseline17·9 (4·3); 24518·0 (4·5); 242\....9 months17·4 (4·2); 22816·2 (4·1); 220−1·18 (−1·85 to −0·50)0·000621 months15·9 (4·0); 21615·4 (3·9); 210−0·57 (−1·26 to 0·12)0·11**PANSS emotional distress**Baseline27·4 (5·6); 24527·0 (5·6); 242\....9 months25·4 (6·3); 22824·1 (6·2); 220−1·08 (−2·02 to −0·13)0·02521 months24·0 (6·0); 21623·4 (6·6); 210−0·27 (−1·24 to 0·70)0·58[^4]Table 3Improvement in PANSS outcomes**Treatment as usual (n=245)Cognitive behavioural therapy plus treatment as usual (n=242)Number needed to treat (95% CI**[\*](#tbl3fn1){ref-type="table-fn"}**)More than 20%**9 months98/216 (45%)96/209 (46%)178 (−11 to 10)21 months74/224 (33%)82/218 (38%)22 (−23 to 8)**More than 25%**9 months57/224 (25%)68/218 (31%)18 (37 to 8)21 months82/216 (38%)80/209 (38%)318 (11 to 11)**More than 50%**9 months11/224 (5%)16/218 (7%)42 (48 to 15)21 months14/216 (7%)28/209 (13%)15 (8 to 81[†](#tbl3fn2){ref-type="table-fn"})**More than 75%**9 months2/224 (1%)2/218 (1%)4070 (57 to 56)21 months2/216 (1%)4/209 (2%)102 (78 to 31)[^5][^6][^7]

The difference between groups on health-related quality of life was 0·028 (95% CI −0·012 to 0·068; p=0·17) at 21 months, and for the Questionnaire about the Process of Recovery, the difference was 2·03 (0·04 to 4·01; p=0·045). Effect estimates for the complete set of secondary outcomes from the linear mixed models are provided in [table 4](#tbl4){ref-type="table"}. The direction of effect favours CBT for all outcomes, but with considerable uncertainty for all but a few outcomes at the end of treatment (positive symptoms, emotional distress, excitement, and voices) and at follow-up (self-rated recovery, emotional distress related to delusions, and CGI improvement).Table 4Secondary outcomes**Treatment as usual (n=245)Cognitive behavioural therapy plus treatment as usual (n=242)Mean difference (95% CI)p valuePSYRATS: auditory hallucinations**Baseline24·9 (12·6); 20021·1 (14·1); 214\....9 months22·4 (13·4); 19217·8 (14·2); 185−2·56 (−4·87 to −0·26)0·02921 months20·3 (14·4); 18217·1 (14·2); 179−1·38 (−3·75 to 0·99)0·26**PSYRATS: delusion**Baseline14·9 (5·3); 23614·3 (5·7); 218\....9 months13·2 (6·7); 21612·2 (6·8); 200−0·42 (−1·61 to 0·77)0·4921 months12·7 (6·8); 20311·4 (7·1); 193−0·76 (−1·98 to 0·46)0·22**PSYRATS unusual beliefs: cognitive**Baseline9·9 (3·5); 2409·6 (3·8); 221\....9 months8·8 (4·3); 2168·2 (4·5); 201−0·24 (−1·01 to 0·54)0·5521 months8·5 (4·4); 2057·8 (4·7); 194−0·35 (−1·14 to 0·44)0·39**PSYRATS unusual beliefs: emotional**Baseline5·0 (2·4); 2384·7 (2·6); 227\....9 months4·4 (2·9); 2193·9 (2·9); 206−0·29 (−0·79 to 0·22)0·2721 months4·3 (2·9); 2063·6 (3·0); 199−0·53 (−1·05 to −0·00)0·049**PSYRATS voices: cognitive**Baseline4·5 (2·5); 2133·9 (2·8); 224\....9 months4·0 (2·7); 2043·4 (2·8); 193−0·32 (−0·82 to 0·17)0·1921 months3·8 (2·8); 1873·3 (2·9); 187−0·17 (−0·68 to 0·34)0·51**PSYRATS voices: emotional**Baseline5·4 (2·8); 2224·7 (3·1); 232\....9 months5·0 (3·0); 2084·2 (3·3); 202−0·43 (−0·95 to 0·08)0·1021 months4·6 (3·3); 1974·1 (3·3); 199−0·03 (−0·55 to 0·50)0·91**PSYRATS voices: physical**Baseline6·2 (3·4); 2235·5 (3·8); 232\....9 months5·7 (3·6); 2094·7 (3·8); 208−0·58 (−1·11 to −0·04)0·03421 months5·1 (3·8); 1984·4 (3·6); 201−0·30 (−0·85 to 0·24)0·28**PSYRATS voices: loudness**Baseline2·6 (1·4); 2392·5 (1·5); 229\....9 months2·3 (1·6); 2192·0 (1·6); 206−0·22 (−0·50 to 0·06)0·1221 months2·3 (1·6); 2061·9 (1·7); 199−0·28 (−0·57 to 0·01)0·056**CDSS**Baseline7·4 (4·7); 2387·1 (4·8); 233\....9 months6·8 (4·8); 2156·3 (4·5); 210−0·54 (−1·31 to 0·23)0·1721 months6·6 (5·1); 2056·0 (4·4); 202−0·50 (−1·28 to 0·29)0·21**ATI**Baseline18·9 (4·9); 23618·2 (4·8); 226\....9 months18·0 (5·0); 20617·5 (5·2); 189−0·07 (−0·88 to 0·73)0·8621 months18·1 (5·0); 19316·9 (5·1); 180−0·60 (−1·44 to 0·24)0·16**PSP**Baseline48·3 (13·5); 24549·2 (15·5); 242\....9 months50·9 (13·9); 22453·2 (14·6); 2131·90 (−0·31 to 4·11)0·09321 months51·4 (14·7); 21451·5 (15·2); 2060·18 (−2·07 to 2·44)0·87**QPR**Baseline47·4 (11·1); 22848·5 (11·4); 216\....9 months48·7 (11·1); 19450·9 (11·6); 1811·88 (−0·03 to 3·79)0·05321 months49·1 (11·7); 18552·0 (9·6); 1652·03 (0·04 to 4·01)0·045**AUDIT**Baseline3·5 (5·4); 2344·3 (6·0); 230\....9 months3·5 (5·7); 2094·4 (6·0); 1940·69 (−0·17 to 1·56)0·1221 months3·2 (5·0); 1934·6 (6·5); 1900·80 (−0·09 to 1·69)0·078**DAST**Baseline0·7 (1·5); 2310·7 (1·4); 224\....9 months0·9 (1·7); 1730·7 (1·7); 153−0·13 (−0·43 to 0·18)0·4121 months0·6 (1·3); 1810·6 (1·3); 1700·12 (−0·17 to 0·41)0·42**Condition improvement CGI**[\*](#tbl4fn1){ref-type="table-fn"}9 months3·3 (1·1); 1573·3 (1·1); 141−0·04 (−0·50 to 0·42)0·8221 months3·5 (1·0); 1473·2 (0·9); 131−0·33 (−0·54 to −0·11)0·013**Severity CGI**Baseline4·8 (0·8); 1624·8 (0·9); 158\....9 months4·3 (1·1); 2134·2 (1·0); 207−0·09 (−0·30 to 0·12)0·4021 months4·2 (1·0); 2124·1 (1·0); 208−0·03 (−0·24 to 0·18)0·77**Participant severity CGI**Baseline4·0 (1·6); 1573·9 (1·4); 152\....9 months3·7 (1·5); 1863·6 (1·7); 1970·06 (−0·27 to 0·39)0·7321 months3·7 (1·6); 2103·7 (1·5); 1930·12 (−0·22 to 0·46)0·48**EQ-5D-5L**Baseline0·703 (0·225); 2300·740 (0·201); 223\....9 months0·721 (0·254); 2050·760 (0·223); 1870·035 (−0·004 to 0·073)0·07921 months0·730 (0·223); 1890·773 (0·204); 1800·028 (−0·012 to 0·068)0·17[^8][^9]

Few serious adverse events occurred and few were attributable to trial participation ([table 5](#tbl5){ref-type="table"}). The total number of adverse events was higher in the group receiving CBT than in the treatment as usual alone group, but this was driven by one participant who had 22 self-harm events. Slightly more participants in the CBT group had an adverse event (107 \[44%\] of 242 *vs* 104 \[42%\] of 245, odds ratio 1·09 (95% CI 0·81--1·46; p=0·58). Fewer suicidal crises and symptom exacerbation or outcome deterioration threshold events occurred in the CBT group than in the treatment as usual group, and no differences in reports of potential unwanted effects of trial participation occurred ([appendix](#sec1){ref-type="sec"}). Participants receiving CBT had weekly contact with trial staff tasked with reporting adverse effects (the trial therapists), whereas participants receiving treatment as usual alone had less frequent contact with trial staff (the trial research assistants) resulting in a maximum of 37 opportunities for such events to be detected in patients receiving CBT and treatment as usual versus seven opportunities for the group receiving treatment as usual alone. This might result in surveillance bias, favouring treatment as usual.Table 5Adverse events and effects**Treatment as usual (n=245)Cognitive behavioural therapy plus treatment as usual (n=242)OR (95% CI)P valueSerious adverse events**Participants who had a trial-related SAE1 (\<1%)2 (1%)\....Life threatening or results in self-harm1\...\...Involuntary hospitalisation..1\....Self-harm requiring treatment at accident and emergency..1\....**Adverse events or effects**Participants who had at least one adverse event or effect104 (42%)107 (44%)1·09 (0·81--1·46)0·58Total adverse events or effects[\*](#tbl5fn1){ref-type="table-fn"}120143\....Death46\....Voluntary hospitalisation2433\....Involuntary hospitalisation1410\....Prolongation of hospitalisation24\....Risk to others02\....Self-harm627\....Suicide attempt32\....Suicidal crisis (CDSS item 8, rating 2)9 months14/224 (6%)12/215 (6%)0·90 (0·40--1·10)0·7921 months7/214 (3%)9/209 (4%)1·35 (0·49--3·73)0·56Severe symptomatic exacerbation: CGI severity of 6 or more9 months25/213 (12%)18/207 (9%)0·69 (0·36--1·33)0·2721 months17/212 (8%)19/208 (9%)1·16 (0·57--2·33)0·69Severe symptomatic exacerbation: CGI improvement of 6 or more[†](#tbl5fn2){ref-type="table-fn"}9 months[‡](#tbl5fn3){ref-type="table-fn"}5/147 (3%)0/131NA0·06221 months6/157 (4%)3/141 (2%)0·45 (0·10--2·02)0·30More than 25% deterioration in PANSS total9 months28/224 (13%)22/218 (10%)0·75 (0·41--1·38)0·3521 months21/216 (10%)15/209 (7%)0·68 (0·33--1·37)0·28More than 50% deterioration in PANSS total9 months7/224 (3%)6/218 (3%)0·77 (0·25--2·43)0·6621 months8/216 (4%)8/209 (4%)0·90 (0·32--2·55)0·84More than 75% deterioration in PANSS total9 months1/224 (\>1%)2/218 (1%)1·78 (0·15--20·95)0·6521 months3/216 (1%)1/209 (1%)0·26 (0·03--2·73)0·26[^10][^11][^12][^13]

Discussion {#cesec100}
==========

In our study assessing whether CBT is an effective treatment for clozapine-resistant schizophrenia, we found no effect of CBT on our primary outcome (21-month PANSS total), although there was a small effect on PANSS total by the end of treatment. The number needed to treat for a good outcome at 21 months, defined using the commonly accepted more than 50% PANSS improvement threshold,[@bib36] was 15, which suggests that CBT can produce worthwhile, lasting outcomes for a proportion of people with clozapine-resistant schizophrenia. However, the threshold for improvement recommended for use with treatment-resistant schizophrenia by an international working group in their consensus guidelines is 20%;[@bib37] the analysis of good outcomes at 21 months using this threshold suggests that little difference exists between CBT and treatment as usual. The high retention and adherence to treatment clearly show that CBT was highly acceptable to participants. Several other small effects on secondary outcomes that are considered to be important occurred at the end of treatment (PANSS positive symptoms, PANSS emotional distress, PANSS excitement, and PSYRATS hallucinations) and at follow-up (self-rated recovery, emotional distress related to delusions, and CGI improvement), although these average effects are unlikely to be clinically significant. The change observed at 21 months on the measure of recovery is encouraging given the debate about the most meaningful outcomes (clinicians tend to prioritise symptom change, whereas service users tend to prioritise improvements in recovery, functioning, and emotion). The absence of association between psychiatric symptoms and recovery is consistent with research showing the indirect effects of symptoms on recovery. There was no suggestion that the addition of CBT to treatment as usual caused more adverse effects. Fewer suicidal crises, symptom exacerbations, and deteriorations occurred in those allocated to CBT. This finding is noteworthy given the increased surveillance and opportunity for these events to be observed in the CBT arm.

Although the benefit of CBT was significant at the end of the treatment (9 months), CBT had no lasting effect on total psychiatric symptoms in clozapine-resistant schizophrenia (at 21 months). This is similar to the observed effects of medications for people with psychosis, which also diminish when treatment ends.[@bib38] The observed average reductions in PANSS total score were lower than the 15 points estimated to be equivalent to a rating of minimal improvement on the CGI scale.[@bib39] The effects on PANSS positive symptoms, PANSS emotional distress, and auditory hallucinations (PSYRATS total) by the end of the treatment show that CBT can change psychotic symptoms, as well as negative emotions, in a large, well conducted, assessor-blind clinical trial. This finding suggests that claims that such effects cannot be replicated under these conditions[@bib17] are unfounded. The effect sizes observed in the FOCUS trial are similar to those found across all heterogeneous but rigorous CBT trials when meta-analysed.[@bib17] The effect sizes are also similar to those found for pharmacological augmentation of clozapine with a second antipsychotic. However, our trial provides stronger evidence, with less risk of bias than the few, small, short-duration, high risk of bias trials in meta-analyses of augmentation with antipsychotics. The adverse effect profile for CBT is also likely to be favourable when compared with the cardiovascular risks associated with multiple antipsychotic medications.[@bib40] Some small lasting effects were observed at 21 months, including on self-rated recovery, which is important to service users; however, these effects are unlikely to reach a threshold of clinically important change.

Despite our trial being methodologically rigorous, several limitations exist. The comparator was treatment as usual, which meant that concealment of allocation from participants was not possible. Additionally, the lack of an active comparator means we are unable to control for non-specific effects such as contact time and a therapeutic relationship. We did not correct for multiple comparisons; therefore, multiple hypothesis testing could have led to type one error. The 26 h of therapy might have been an insufficient length for patients with clozapine-resistant schizophrenia, who have problems with memory, negative symptoms, and side-effects of polypharmacy, which would be consistent with other trials of CBT for similar populations.[@bib41] A small number of participants met criteria for diagnoses other than schizophrenia (eg, delusional disorder), which might have reduced the homogeneity of the sample. Arguably, participants who were unable to tolerate clozapine due to side-effects could meet criteria for treatment-resistant schizophrenia rather than clozapine-resistant schizophrenia; however, alternatives to clozapine are still required for such a population, and the sensitivity analysis excluding those who discontinued clozapine found a similar pattern of results. Similarly, we did not routinely assess clozapine blood levels, nor did we assess response to placebo before randomisation therefore, some of our participants might not have been truly clozapine resistant. The mean baseline PANSS total score of 83 suggests that, on average, our participants were moderately ill; however, our entry criteria were also modified to include those who were at least mildly ill (ie, at least 58), whereas Honer\'s trial[@bib11] had a minimum of 80 for inclusion. Although attempts were made to minimise the likelihood of allegiance bias (eg, masking of assessors), this possibility remains.

Some might argue that, since positive symptoms are the target of clozapine, and are often considered the primary target of CBT for psychosis, they would have been a more appropriate primary outcome for this trial. We chose severity of total symptoms of schizophrenia because the FOCUS trial was a pragmatic effectiveness trial. A similar pattern was seen with PANSS positive symptoms and PSYRATS hallucinations showing significant effects at the end of treatment but not at follow-up. Therefore, a similar overall conclusion is likely to have been reached if the trial had chosen to use a specific measure of positive symptoms as the primary outcome. The choice regarding the timing of the primary outcome is more likely to have influenced the overall conclusion. If end of treatment had been selected, the conclusion would probably have been that CBT is of benefit to people with clozapine-resistant psychosis, but the effect does not persist.

Our results do not support a recommendation to routinely offer CBT for clozapine-resistant schizophrenia. Offering it as a pragmatic individual trial might be worthwhile, particularly in cases where distressing positive symptoms exist or where service users are reluctant to consider pharmacological augmentation because of probable side-effect burden. CBT should probably be offered earlier in the course of psychosis, since individuals with a long history of mental health problems and a lack of response to pharmacological interventions might also be less likely to benefit from psychological interventions than those with psychoses who are more responsive to antipsychotic medications.

Given that more people with clozapine-resistant schizophrenia showed a good clinical outcome to CBT with treatment as usual than those to treatment as usual alone, it is important to be able to identify factors that might predict who is going to benefit. Identification of responders to CBT might be possible by use of trajectory analysis, risk modelling, or methods such as cluster analysis. Future research should examine how intensive psychological treatment needs to be after 9 months to maintain the effects observed at the end of treatment. Further consideration should also be given to the most appropriate and valued outcomes for this population. For individuals who do not respond to clozapine or CBT, attempting to increase wellbeing, subjective recovery, and social functioning might be more successful than attempting to reduce symptoms, and might be more important to service users and their families.

In conclusion, there was no lasting effect of CBT for clozapine-resistant schizophrenia on our primary outcome of psychiatric symptoms at 21 months. However, CBT was highly acceptable, produced small but significant improvements in psychiatric symptoms at the end of treatment (9 months) and a lasting improvement on self-rated recovery (21 months), with little evidence of adverse effects. Entrenched symptoms might need a longer period of continuing psychological intervention, similar to the use of medication.
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[^1]: Members of the FOCUS trial group are listed at the end of the paper

[^2]: Data are mean (SD), n (%), or median (IQR); N.

[^3]: Not due to a substance or known physiological condition.

[^4]: Data are mean (SD); N, unless otherwise stated. PANSS=Positive and Negative Syndrome Scale.

[^5]: Data are n/N (%), unless otherwise stated. The Positive and Negative Syndrome Scale (PANSS) is rescaled.

[^6]: Number needed to treat (harm) to number needed to treat (benefit).

[^7]: Number needed to treat (benefit) to number needed to treat (benefit).

[^8]: Data are mean (SD); N, unless otherwise stated. PSYRATS=Psychotic Symptom Rating Scales. CDSS=Calgary Depression Rating Scale for Schizophrenia. ATI=Anxious Thoughts Inventory. PSP=Personal and Social Performance Scale. QPR=Questionnaire about the Process of Recovery. AUDIT=Alcohol Use Disorder Test. DAST=Drug Abuse Screening Test. CGI=Clinical Global Impression Scale. EQ-5D-5L=health status and health-related utility.

[^9]: Analysed separately at 9 and 21 months because baseline score was not collected.

[^10]: Data are n, n (%), or n/N (%), unless otherwise stated. SAE=serious adverse event. CDSS=Calgary Depression Rating Scale for Schizophrenia. CGI=Clinical Global Impression Scale. NA=not applicable. PANSS=Positive and Negative Syndrome Scale.

[^11]: Two participants had two involuntary hospitalisations, one participant had 22 self-harm events, one participant had two self-harm events, and nine participants had two voluntary hospitalisations.

[^12]: High scores indicate deterioration.

[^13]: χ^2^ test.
